Abstract
IMPORTANCE: Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants. OBJECTIVES To investigate the effects of known Alzheimer disease risk loci in modifying AAO and to estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium. DESIGN, SETTING, AND PARTICIPANTS: The Alzheimer Disease Genetics Consortium comprises 14 case-control, prospective, and family-based data sets with data on 9162 participants of white race/ethnicity with Alzheimer disease occurring after age 60 years who also had complete AAO information, gathered between 1989 and 2011 at multiple sites by participating studies. Data on genotyped or imputed single-nucleotide polymorphisms most significantly associated with risk at 10 confirmed LOAD loci were examined in linear modeling of AAO, and individual data set results were combined using a random-effects, inverse variance-weighted meta-analysis approach to determine whether they contribute to variation in AAO. Aggregate effects of all risk loci on AAO were examined in a burden analysis using genotype scores weighted by risk effect sizes. MAIN OUTCOMES AND MEASURES: Age at disease onset abstracted from medical records among participants with LOAD diagnosed per standard criteria. RESULTS: Analysis confirmed the association of APOE with earlier AAO (P = 3.3 × 10-96), with associations in CR1 (rs6701713, P = 7.2 × 10-4), BIN1 (rs7561528, P = 4.8 × 10-4), and PICALM (rs561655, P = 2.2 × 10-3) reaching statistical significance (P < .005). Risk alleles individually reduced AAO by 3 to 6 months. Burden analyses demonstrated that APOE contributes to 3.7%of the variation in AAO (R2 = 0.256) over baseline (R2 = 0.221), whereas the other 9 loci together contribute to 2.2%of the variation (R2 = 0.242). CONCLUSIONS AND RELEVANCE: We confirmed an association of APOE (OMIM 107741) variants with AAO among affected participants with LOAD and observed novel associations of CR1 (OMIM 120620), BIN1 (OMIM 601248), and PICALM (OMIM 603025) with AAO. In contrast to earlier hypothetical modeling, we show that the combined effects of Alzheimer disease risk variants on AAO are on the scale of, but do not exceed, the APOE effect. While the aggregate effects of risk loci on AAO may be significant, additional genetic contributions to AAO are individually likely to be small.
Original language | English |
---|---|
Pages (from-to) | 1394-1404 |
Number of pages | 11 |
Journal | JAMA Neurology |
Volume | 71 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2014 |
Bibliographical note
Publisher Copyright:Copyright 2014 American Medical Association. All rights reserved.
Funding
Funders | Funder number |
---|---|
Alzheimer's Association | IIRG-05-14147, IIRG-08-89720 |
Coins for Alzheimer's Research Trust | |
AstraZeneca | |
Boston University School of Public Health/Boston University Medical Campus | P30 AG013846, U01 AG10483, R01 AG017173, R01 MH080295, R01AG33193, R01 AG025259, R01 CA129769 |
Bristol-Myers Squibb | |
Canadian Institutes of Health Research | |
Columbia University | P50 AG008702, R37 AG015473 |
Charles A Dana Foundation | |
Duke-Kunshan University | AG05128, P30 AG028377 |
Eli Lilly and Company | |
University Research Committee, Emory University | AG025688 |
GE Healthcare | |
Genentech Incorporated | |
GlaxoSmithKline | |
Higher Education Funding Council for England | |
Howard Hughes Medical Institute | |
University of Southern Indiana | P30 AG10133 |
Johnson and Johnson Pharmaceutical Research and Development | |
Massachusetts General Hospital | P50 AG005134 |
Mayo Clinic Rochester | P50 AG016574 |
Medical Research Council | |
National Institute of Biomedical Imaging and Bioengineering | |
National Institute of Mental Health | MH60451 |
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council | NS39764 |
National Institute on Aging | RC2 AG036535, AG034504, U01 AG024904, K01 AG030514 |
York University, New York, New York, USA bbbUniversity of Rochester, Rochester, New York | UL1 RR029893, P30 AG08051, 1RC2AG036502, 5R01AG012101, MO1RR00096, 5R01AG022374, 1R01AG035137, 5R01AG013616 |
Newcastle University | |
Northwestern Polytechnical University | P30 AG013854 |
Biomedical Laboratory Research and Development, VA Office of Research and Development | |
Oregon Health and Science University | P30 AG008017, R01 AG026916 |
Pfizer | |
Schering Plough Co | |
Stichting MS Research | |
University of California, Los Angeles | P50 AG016570 |
Miami Clinical and Translational Science Institute, University of Miami | AG027944, AG021547, R01 AG027944, AG010491, AG019757 |
University of Southern California | P50 AG005142 |
Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center | R01 AG019085 |
Wellcome Trust | |
National Center for Advancing Translational Sciences (NCATS) | UL1TR000135 |
National Center for Advancing Translational Sciences (NCATS) |
ASJC Scopus subject areas
- Clinical Neurology